Doheny Eye Institute, University of California, Los Angeles, CA, USA.
Jaeb Center for Health Research, Tampa, FL, USA.
Transl Vis Sci Technol. 2024 Jul 1;13(7):19. doi: 10.1167/tvst.13.7.19.
Compare choroidal changes in ranibizumab versus panretinal photocoagulation (PRP)-treated eyes with proliferative diabetic retinopathy (PDR).
DRCR Retina Network Protocol S post hoc analysis evaluated optical coherence tomography change in choroidal thickness (subfoveal and 3mm superior and inferior to the fovea) through five years; choroidal vascularity index (CVI) was assessed at baseline and one year. Mixed linear models for choroidal change included adjustments for the baseline choroidal value and age.
This study included 328 eyes (158 ranibizumab and 170 PRP) from 256 participants (88 ranibizumab and 95 PRP eyes at five years). Mean change in choroidal thickness from baseline to five years at the fovea was -12 µm in ranibizumab versus -8 µm in PRP (difference [95% confidence interval]: -4 [-18 to 10], P = 0.57), superior was -14 µm versus -19 µm (difference: 5 [-8 to 17], P = 0.45) and inferior was -26 µm versus -32 µm [difference: 5 (-9 to 20), P = 0.45]; change at all three points within the ranibizumab group, and the superior and inferior points for PRP, were statistically significant (P < .05). Mean change in CVI at one year was -0.02% in ranibizumab versus -0.95% in PRP (difference: 0.93 [-0.35 to 2.21], P = 0.14).
In patients with PDR, treatment with ranibizumab versus PRP did not result in statistically significant differences in five-year choroidal thickness or one-year CVI change. Both groups had significant decreases in choroidal thickness at five years.
Ranibizumab treatment for PDR did not statistically significantly affect choroidal thickness or vascularity differently than PRP.
比较增生型糖尿病视网膜病变（PDR）患者接受雷珠单抗（ranibizumab）与全视网膜光凝（PRP）治疗后的脉络膜变化。
DRCR 视网膜网络协议 S 的事后分析通过五年时间评估了脉络膜厚度（黄斑下和黄斑上 3mm 处）的光学相干断层扫描变化；在基线和一年时评估了脉络膜血管指数（CVI）。脉络膜变化的混合线性模型包括对基线脉络膜值和年龄的调整。
本研究纳入了来自 256 名患者的 328 只眼（5 年时 158 只眼接受雷珠单抗治疗，170 只眼接受 PRP 治疗）（5 年时 88 只眼接受雷珠单抗治疗，95 只眼接受 PRP 治疗）。从基线到五年时黄斑中心凹处脉络膜厚度的平均变化在雷珠单抗组为-12μm，在 PRP 组为-8μm（差异[-18 至 10]，P=0.57），上方为-14μm 比-19μm（差异：5[-8 至 17]，P=0.45），下方为-26μm 比-32μm（差异：5[-9 至 20]，P=0.45）；雷珠单抗组所有三个部位的变化，以及 PRP 的上方和下方部位的变化，均有统计学意义（P<.05）。雷珠单抗组一年时 CVI 的平均变化为-0.02%，PRP 组为-0.95%（差异：0.93[-0.35 至 2.21]，P=0.14）。
在 PDR 患者中，与 PRP 相比，雷珠单抗治疗五年后脉络膜厚度或一年后 CVI 变化无统计学显著差异。两组患者在五年时均出现脉络膜厚度显著下降。
为了使译文更流畅，我对原句中的语序进行了调整。
